Table 5. Results of the multiple comparisons of the drugs that showed differences between groups or periods.
| Variable | Group/period | Comparison | Mean difference | Standard error | gf | p Lower |
CI (95%) | ||
|---|---|---|---|---|---|---|---|---|---|
| Upper | |||||||||
| Naproxen | Control | Pre and | 1 month | -1.28 | 0.49 | 1 | 0.131 | -2.70 | 0.15 |
| Pre and | 3 months | -6.66 | 1.49 | 1 | <0.001 | -11.03 | -2.28 | ||
| 1 month and | 3 months | -5.38 | 1.47 | 1 | 0.004 | -9.68 | -1.08 | ||
| Study | Pre and | 1 month | 0.57 | 0.46 | 1 | >0.999 | -0.77 | 1.91 | |
| Pre and | 3 months | -0.50 | 0.64 | 1 | >0.999 | -2.37 | 1.37 | ||
| 1 month and | 3 months | -1.07 | 0.53 | 1 | 0.674 | -2.64 | 0.50 | ||
| Pre | Control and | Study | -0.89 | 0.47 | 1 | 0.866 | -2.26 | 0.48 | |
| 1 month | Control and | Study | 0.96 | 0.56 | 1 | >0.999 | -0.68 | 2.60 | |
| 3 months | Control and | Study | 5.27 | 1.56 | 1 | 0.011 | 0.68 | 9.86 | |
| Dipyrone | Control | Pre and | 1 month | -2.96 | 1.95 | 1 | >0.999 | -8.69 | 2.76 |
| Pre and | 3 months | -4.69 | 2.31 | 1 | 0.638 | -11.47 | 2.10 | ||
| 1 month and | 3 months | -1.72 | 2.49 | 1 | >0.999 | -9.04 | 5.59 | ||
| Study | Pre and | 1 month | 5.71 | 1.51 | 1 | 0.002 | 1.29 | 10.14 | |
| Pre and | 3 months | -1.11 | 2.26 | 1 | >0.999 | -7.73 | 5.51 | ||
| 1 month and | 3 months | -6.82 | 1.71 | 1 | 0.001 | -11.85 | -1.80 | ||
| Pre | Control and | Study | -1.77 | 1.89 | 1 | >0.999 | -7.33 | 3.78 | |
| 1 month | Control and | Study | 6.91 | 1.74 | 1 | 0.001 | 1.80 | 12.01 | |
| 3 months | Control and | Study | 1.81 | 2.64 | 1 | >0.999 | -5.93 | 9.55 | |
| Paracetamol | Both groups | Pre and | 1 month | -0.93 | 1.39 | 1 | >0.999 | -4.26 | 2.40 |
| Pre and | 3 months | -13.25 | 3.02 | 1 | <0.001 | -20.47 | -6.02 | ||
| 1 month and | 3 months | -12.32 | 2.58 | 1 | <0.001 | -18.50 | -6.13 | ||
| Codeine | Both groups | Pre and | 1 month | 0.60 | 1.02 | 1 | >0.999 | -1.84 | 3.04 |
| Pre and | 3 months | -13.60 | 2.80 | 1 | <0.001 | -20.30 | -6.91 | ||
| 1 month and | 3 months | -14.21 | 2.49 | 1 | <0.001 | -20.17 | -8.25 | ||
| Tramadol | Both groups | Pre and | 1 month | 0.36 | 0.15 | 1 | 0.047 | 0.00 | 0.72 |
| Pre and | 3 months | -1.13 | 0.33 | 1 | 0.002 | -1.91 | -0.35 | ||
| 1 month and | 3 months | -1.49 | 0.29 | 1 | <0.001 | -2.18 | -0.80 | ||
| Cyclobenzaprine | Both groups | Pre and | 1 month | 2.44 | 0.88 | 1 | 0.017 | 0.33 | 4.56 |
| Pre and | 3 months | -1.03 | 1.27 | 1 | >0.999 | -4.06 | 2.00 | ||
| 1 month and | 3 months | -3.47 | 0.97 | 1 | 0.001 | -5.80 | -1.14 | ||
| Omeprazole or ranitidine | Control | Pre and | 1 month | -3.28 | 1.34 | 1 | 0.215 | -7.20 | 0.65 |
| Pre and | 3 months | -10.55 | 2.83 | 1 | 0.003 | -18.85 | -2.25 | ||
| 1 month and | 3 months | -7.28 | 2.33 | 1 | 0.027 | -14.11 | -0.44 | ||
| Study | Pre and | 1 month | 8.11 | 1.96 | 1 | 0.001 | 2.35 | 13.86 | |
| Pre and | 3 months | 5.43 | 2.21 | 1 | 0.210 | -1.06 | 11.91 | ||
| 1 month and | 3 months | -2.68 | 1.07 | 1 | 0.184 | -5.82 | 0.46 | ||
| Pre | Control and | Study | -6.51 | 2.84 | 1 | 0.328 | -14.85 | 1.82 | |
| 1 month | Control and | Study | 4.87 | 2.14 | 1 | 0.342 | -1.41 | 11.15 | |
| 3 months | Control and | Study | 9.47 | 3.58 | 1 | 0.122 | -1.03 | 19.96 | |
Bonferroni's multiple comparisons